e-learning
resources
Milan 2017
Tuesday, 12.09.2017
Management of COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Target engagement confirmed in man with a dipeptidyl peptidase 1 inhibitor
J. Mäenpää (Mölndal, Sweden)
Source:
International Congress 2017 – Management of COPD
Session:
Management of COPD
Session type:
Poster Discussion
Number:
3251
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Mäenpää (Mölndal, Sweden). Target engagement confirmed in man with a dipeptidyl peptidase 1 inhibitor. 3251
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
Dipeptidyl peptidase IV and aminopeptidase N activity in children with sleep apnea
Source: Eur Respir J 2005; 26: Suppl. 49, 357s
Year: 2005
Dipeptidyl peptidase I (DPPI) cleaves surfactant protein D (SP-D): A mechanism for immune compromise in the lung
Source: International Congress 2016 – Molecular immunology of the lung
Year: 2016
Human airway trypsin-like protease stimulates protease activated receptors and interactions of these receptors
Source: International Congress 2019 – Immunopathological mechanisms of lung disease
Year: 2019
Human alpha-1 proteinase inhibitor (tal6004) manufacturing process and pathogen safety
Source: Annual Congress 2009 - Treatment of airways disease
Year: 2009
Dipeptidyl peptidase-4 (DPP-4) may predict response to tralokinumab in patients with asthma
Source: International Congress 2016 – Asthma: from basic mechanisms to novel therapeutic perspectives
Year: 2016
Development of the first protease multiplex immunoassay for active neutrophilic serine protease biomarkers
Source: Virtual Congress 2021 – Biomarkers for the management of bronchial obstructive diseases
Year: 2021
LATE-BREAKING ABSTRACT: Lack of association between circulating dipeptidyl peptidase-4 and type 2 biomarkers in asthma; data from U-BIOPRED and BIOAIR cohorts
Source: International Congress 2016 – Laboratory tests and cell biology in allergy and immunology
Year: 2016
LSC Abstract – A functional variant of secretory leukocyte protease inhibitor (SLPI) with improved anti-inflammatory activity against pulmonary infection
Source: International Congress 2015 – Immunomodulation: basic science and clinical aspects
Year: 2015
Expression of adamalysin proteases (A Disintegrin And Metalloprotease) and their inhibitors in sputum from asthmatics
Source: Eur Respir J 2006; 28: Suppl. 50, 445s
Year: 2006
A functional variant of secretory leukocyte protease inhibitor (SLPI) with improved anti-inflammatory activity against pulmonary infection
Source: Lung Science Conference 2015
Year: 2015
AZD9668: Pharmacological characterisation of a novel oral inhibitor of neutrophil elastase (NE)
Source: Annual Congress 2010 - Pre-clinical models of airways disease
Year: 2010
SerpinB1 in cystic fibrosis airway fluids: quantity, molecular form and mechanism of elastase inhibition
Source: Eur Respir J 2011; 37: 1083-1090
Year: 2011
Type II transmembrane serine protease matriptase is a mediator of pulmonary fibrosis
Source: Annual Congress 2013 –Translational studies in chronic repair and remodelling in the lung
Year: 2013
Molecular and cellular profile of the structurally novel phosphodiesterase (PDE) 4 inhibitor, BAY 19-8004
Source: Eur Respir J 2001; 18: Suppl. 33, 36s
Year: 2001
Development of secretory leukocyte protease inhibitor (SLPI) variants resistant to degradation by neutrophil elastase
Source: International Congress 2014 – New studies into pulmonary proteases and antiproteases
Year: 2014
NIK-616,a new type of selective PDE IV inhibitor with reduced emetic activity
Source: Eur Respir J 2002; 20: Suppl. 38, 618s
Year: 2002
Phase 1 trial of a novel chemokine inhibitor
Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies
Year: 2019
The phosphodiesterase 4 inhibitor SB 207499 selectively inhibits neutrophil functions
Source: Eur Respir J 2001; 18: Suppl. 33, 34s
Year: 2001
Alpha-1 antitrypsin genotypes and associated inhibitory activity towards neutrophil serine proteinases, in vitro
Source: International Congress 2015 – Promising novel findings in translational pulmonary research
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept